Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million for proof-of-concept testing of a lead program in ...
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results